PHARMACYTE BIOTECH, INC. Increase (Decrease) in Prepaid Expense and Other Assets
PHARMACYTE BIOTECH, INC. (PMCB) reported Increase (Decrease) in Prepaid Expense and Other Assets of $123.51 thousand for the 3-month period ending 2026-07-31, per its 10-Q filed 2026-09-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-09-14
- PHARMACYTE BIOTECH, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-07-31 was $123.51K, a 756.45% increase year-over-year.
- PHARMACYTE BIOTECH, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-04-30 was $316.48K, a 1830.12% increase year-over-year.
- PHARMACYTE BIOTECH, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-01-31 was -$344.48K.
- PHARMACYTE BIOTECH, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-10-31 was $264.97K, a 4.74% increase year-over-year.
- PHARMACYTE BIOTECH, INC. increase (decrease) in prepaid expense and other assets for fiscal 2026 was $251.39K.
- PHARMACYTE BIOTECH, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$36.04K, a 123.69% decline from fiscal 2024.
- PHARMACYTE BIOTECH, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $152.12K, a 1026.06% increase from fiscal 2023.
- PHARMACYTE BIOTECH, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $13.51K, a 35.80% decline from fiscal 2022.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-07-31 | $123.51K 10-Q · filed 2026-09-14 | $439.99K derived: sum of 2 quarters · filed 2026-09-14 | $95.51K derived: sum of 3 quarters · filed 2026-09-14 | $360.47K derived: sum of 4 quarters · filed 2026-09-14 |
| 2026-04-30 | $316.48K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | -$28.00K derived: sum of 2 quarters · filed 2026-07-29 | $236.97K derived: sum of 3 quarters · filed 2026-07-29 | $251.39K 10-K · filed 2026-07-29 |
| 2026-01-31 | -$344.48K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | -$79.52K derived: sum of 2 quarters · filed 2026-03-17 | -$65.09K 10-Q · filed 2026-03-17 | -$48.70K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-10-31 | $264.97K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-18 | $279.39K 10-Q · filed 2025-12-18 | $295.79K derived: sum of 3 quarters · filed 2026-09-14 | $9.93K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-07-31 | $14.42K 10-Q · filed 2026-09-14 | $30.82K derived: sum of 2 quarters · filed 2026-09-14 | -$255.03K derived: sum of 3 quarters · filed 2026-09-14 | -$2.05K derived: sum of 4 quarters · filed 2026-09-14 |
| 2025-04-30 | $16.40K derived: 10-K 12 month − 10-Q 9 month · filed 2026-07-29 | -$269.45K derived: sum of 2 quarters · filed 2026-07-29 | -$16.47K derived: sum of 3 quarters · filed 2026-07-29 | -$36.04K 10-K · filed 2026-07-29 |
| 2025-01-31 | -$285.85K derived: 10-Q 9 month − 10-Q 6 month · filed 2026-03-17 | -$32.87K derived: sum of 2 quarters · filed 2026-03-17 | -$52.44K 10-Q · filed 2026-03-17 | -$90.40K derived: sum of 4 quarters · filed 2026-03-17 |
| 2024-10-31 | $252.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-12-18 | $233.41K 10-Q · filed 2025-12-18 | $195.45K derived: sum of 3 quarters · filed 2025-12-18 | $170.02K derived: sum of 4 quarters · filed 2025-12-18 |
| 2024-07-31 | -$19.57K 10-Q · filed 2025-09-15 | -$57.53K derived: sum of 2 quarters · filed 2025-09-15 | -$82.96K derived: sum of 3 quarters · filed 2025-09-15 | $151.58K derived: sum of 4 quarters · filed 2025-09-15 |
| 2024-04-30 | -$37.96K derived: 10-K 12 month − 10-Q 9 month · filed 2025-08-11 | -$63.39K derived: sum of 2 quarters · filed 2025-08-11 | $171.15K derived: sum of 3 quarters · filed 2025-08-11 | $152.12K 10-K · filed 2025-08-11 |
| 2024-01-31 | -$25.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-03-17 | $209.11K derived: sum of 2 quarters · filed 2025-03-17 | $190.08K 10-Q · filed 2025-03-17 | $116.75K derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-10-31 | $234.54K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-12-13 | $215.51K 10-Q · filed 2024-12-13 | $142.18K derived: sum of 3 quarters · filed 2024-12-13 | $66.38K derived: sum of 4 quarters · filed 2024-12-13 |
| 2023-07-31 | -$19.03K 10-Q · filed 2024-09-17 | -$92.36K derived: sum of 2 quarters · filed 2024-09-17 | -$168.16K derived: sum of 3 quarters · filed 2024-09-17 | $60.50K derived: sum of 4 quarters · filed 2024-09-17 |
| 2023-04-30 | -$73.33K derived: 10-K 12 month − 10-Q 9 month · filed 2024-08-13 | -$149.13K derived: sum of 2 quarters · filed 2024-08-13 | $79.53K derived: sum of 3 quarters · filed 2024-08-13 | $13.51K 10-K · filed 2024-08-13 |
| 2023-01-31 | -$75.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-03-18 | $152.86K derived: sum of 2 quarters · filed 2024-03-18 | $86.84K 10-Q · filed 2024-03-18 | $6.91K derived: sum of 4 quarters · filed 2024-03-18 |
| 2022-10-31 | $228.66K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-12-15 | $162.64K 10-Q · filed 2023-12-15 | $82.71K derived: sum of 3 quarters · filed 2023-12-15 | $15.01K derived: sum of 4 quarters · filed 2023-12-15 |
| 2022-07-31 | -$66.02K 10-Q · filed 2023-09-18 | -$145.95K derived: sum of 2 quarters · filed 2023-09-18 | -$213.65K derived: sum of 3 quarters · filed 2023-09-18 | -$291.91K derived: sum of 4 quarters · filed 2023-09-18 |
| 2022-04-30 | -$79.93K derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-31 | -$147.63K derived: sum of 2 quarters · filed 2023-07-31 | -$225.89K derived: sum of 3 quarters · filed 2023-07-31 | $21.04K 10-K · filed 2023-07-31 |
| 2022-01-31 | -$67.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-03-16 | -$145.96K derived: sum of 2 quarters · filed 2023-03-16 | $100.97K 10-Q · filed 2023-03-16 | $132.39K derived: sum of 4 quarters · filed 2023-03-16 |
| 2021-10-31 | -$78.26K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-12-14 | $168.67K 10-Q · filed 2022-12-14 | $200.09K derived: sum of 3 quarters · filed 2022-12-14 | $146.84K derived: sum of 4 quarters · filed 2022-12-14 |
| 2021-07-31 | $246.93K 10-Q · filed 2022-09-14 | $278.35K derived: sum of 2 quarters · filed 2022-09-14 | $225.10K derived: sum of 3 quarters · filed 2022-09-14 | $183.53K derived: sum of 4 quarters · filed 2022-09-14 |
| 2021-04-30 | $31.42K derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-28 | -$21.83K derived: sum of 2 quarters · filed 2022-07-28 | -$63.41K derived: sum of 3 quarters · filed 2022-07-28 | -$69.65K 10-K · filed 2022-07-28 |
| 2021-01-31 | -$53.25K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-03-15 | -$94.83K derived: sum of 2 quarters · filed 2022-03-15 | -$101.08K 10-Q · filed 2022-03-15 | |
| 2020-10-31 | -$41.57K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-12-14 | -$47.82K 10-Q · filed 2021-12-14 | ||
| 2020-07-31 | -$6.25K 10-Q · filed 2021-09-14 | |||
| 2020-01-31 | -$97.33K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-03-12 | -$82.34K derived: sum of 2 quarters · filed 2021-03-12 | -$71.20K 10-Q · filed 2021-03-12 | |
| 2019-10-31 | $14.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-12-11 | $26.13K 10-Q · filed 2020-12-11 | ||
| 2019-07-31 | $11.14K 10-Q · filed 2020-09-11 | |||
| 2017-01-31 | -$88.83K 10-Q · filed 2017-03-13 | |||
| 2016-01-31 | -$110.84K 10-Q · filed 2017-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |